Invex Therapeutics
- Short interest
- 0.00%
- 0.00 pp 30d
- as of 1 Oct 2025
- Reported shorts
- 3.5K
- Shares on issue
- 75.154M
Invex Therapeutics (IXC) financials
Results, ratios and statements
Latest result
Year to 30 Jun 2026 (FY26) vs FY25, figures in AUD, the reporting currency
- Revenue
- $175.2KM (source: ASX (Markit))vs $461.5KM (source: ASX (Markit)) (FY25)
- ASX (Markit), as at 14 Oct 2026
- NPAT
- −$1.4MM (source: ASX (Markit))vs −$476.9K (FY25)
- ASX (Markit), as at 14 Oct 2026
- EPS (diluted)
- −$0.018T (source: Derived: trailing 12 months at year end)vs −$0.006 (FY25)
- Derived: trailing 12 months at year end, as at 14 Oct 2026
- Rev YoY
- −62.0%FY
- EPS YoY
- n/aTTM
- ASX (Markit)
- Derived: trailing 12 months at year end
Summary of Appendix 4E and Annual Report to shareholders, 31 Aug 2026
Invex Therapeutics reported a statutory net loss after tax of $1.35 million for FY2026, a 184% widening from the prior year's $0.48 million loss, with no dividend declared. The company is focused on repurposing Exenatide for neurological conditions and continues to progress pre-clinical development.
Automated summary of the filing; the filing itself is the record.
Key ratios
Year to 30 Jun 2026 (FY); no balance sheet aligned with this period; prices to 14 Oct 2026
- Gross margin
- n/a
- Operating margin
- n/a
- Net margin
- −772.1%
- FCF margin
- n/a
- ROE
- n/a
- ROA
- n/a
- FCF conversion
- n/a
- Net debt (excl. leases)
- n/a
- Net debt / EBITDA
- n/a
- Current ratio
- n/a
- Interest cover
- n/a
- Cash dividends paid / net profit
- n/a
- Market cap
- n/a (no share count we can vouch for)
- P/E
- n/a
- P/B
- n/a (no share count we can vouch for)
Ratios use the reporting currency (AUD); market cap is in AUD. Source: ASX (Markit), as at 14 Oct 2026.
Financial statements
Figures in AUD, the reporting currency; Yahoo Finance unless marked
| Line item | FY26 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Revenue | $175.2KM (source: ASX (Markit)) | $461.5KM (source: ASX (Markit)) | $1.7MM (source: ASX (Markit)) | $1.3MM (source: ASX (Markit)) |
| Operating income | n/a | −$951.2K | −$3.3M | −$9.0M |
| EBITDA | n/a | −$951.2K | −$3.3M | −$9.0M |
| EBIT | n/a | −$951.2K | −$3.3M | −$9.0M |
| Pretax income | n/a | −$476.9K | −$1.6M | −$7.7M |
| Tax | n/a | $0 | $0 | $0 |
| NPAT | −$1.4MM (source: ASX (Markit)) | −$476.9K | −$1.6M | −$7.7M |
| Net interest income | n/a | $232.4K | $491.8K | $797.1K |
| EPS basic | −$0.018T (source: Derived: trailing 12 months at year end) | −$0.006 | −$0.022 | −$0.10 |
| EPS diluted | −$0.018T (source: Derived: trailing 12 months at year end) | −$0.006 | −$0.022 | −$0.10 |
| Shares | n/a | 75.2M | 75.2M | 75.2M |
- ASX (Markit)
- Derived: trailing 12 months at year end
Financial reports
The company's own filings, newest first
- Appendix 4E and Annual Report to shareholdersAnnual Results31 Aug 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report23 Jul 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report24 Apr 2026via asx_announcements
- Appendix 4D and Half Year ReportHalf Year Results12 Feb 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report22 Jan 2026via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report3 Oct 2025via asx_announcements
- Appendix 4E and Annual Report to shareholdersAnnual Results11 Aug 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report23 Jul 2025via asx_announcements
- Quarterly Activities/Appendix 4C Cash Flow ReportQuarterly Report8 Apr 2025via asx_announcements
- Appendix 4D and Half Year ReportHalf Year Results7 Feb 2025via asx_announcements
Showing 10 of 69 reports